What is the 13F Pro Quality Score for ALZN?

13F Pro ranks Alzamend Neuro, Inc. (ALZN) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View ALZN's current score at https://13fpro.ai/company/ALZN (free sign-up required for the full ranking).

Where does 13F Pro source ALZN data?

All Alzamend Neuro, Inc. fundamentals and ownership data come directly from SEC EDGAR. Alzamend Neuro, Inc. files with the SEC under CIK 1677077. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is ALZN in?

Alzamend Neuro, Inc. (ALZN) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is ALZN research updated on 13F Pro?

ALZN's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Alzamend Neuro, Inc.(ALZN)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqsmall

Institutional-grade research for retail investors

SEC EDGAR: CIK 1677077 ALZN stock profile & AI dashboard →

13F Pro Quality Score

30.2/100

Rank #2,504 of 2,964 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

30.0/100

Profitability

30.0/100

Balance Sheet

0.9/100

Earnings Quality

26.3/100

Free Cash Flow

30.0/100

Institutional Flow

99.5/100

Revenue Scale

30.0/100

Dilution Risk

30.0/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why ALZN Scores 30/100

exact factor attribution · 2026-09-10

ALZN's composite is driven by institutional flow, held back by capital efficiency and revenue growth. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Institutional flow

+2.5 pts

100th pct

Earnings growth

-1.0 pts

30th pct

Shareholder dilution

-1.0 pts

30th pct

Earnings quality

-2.4 pts

26th pct

Free cash flow

-3.0 pts

30th pct

Profitability

-3.0 pts

30th pct

Scale

-3.0 pts

30th pct

Revenue growth

-4.0 pts

30th pct

Capital efficiency

-4.9 pts

1th pct

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

ALZN Stock Analysis & AI Quality Score

Data updated 2026-09-10

AI stock analysis and institutional research for Alzamend Neuro, Inc. (ALZN), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ALZN at 30.2/100 on a 32-signal composite quality model, placing it at rank #2,504 of 2,964 stocks — the bottom half of the AI-ranked universe. ALZN scores in the top quartile across institutional flow (99.5). Areas of concern include balance sheet strength (0.9) and earnings quality (26.3), which score below median versus the broader universe. Shareholder dilution risk is elevated at 30.0/100, reflecting ongoing share issuance or stock-based compensation. Top institutional holders of ALZN by reported 13-F value include KMT WEALTH MANAGEMENT, Kingsbury Capital Investment Advisors, GEODE CAPITAL MANAGEMENT, based on the most recent SEC filings. ALZN trades on the Nasdaq exchange and files with the SEC under CIK 1677077. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ALZN daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Alzamend Neuro, Inc. directly from SEC EDGAR.

Net Income

Q2 2026

$-3.0M

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Net Income

-94.3% YoY

$-8.8MFY 2026

FY23 $-14.9MFY24 $-9.9MFY25 $-4.5MFY26 $-8.8M

Operating Income

-95.0% YoY

$-8.8MFY 2026

FY23 $-14.9MFY24 $-9.9MFY25 $-4.5MFY26 $-8.8M

EPS (Diluted)

+76.8% YoY

$-2.63FY 2026

FY23 $-22.89FY24 $-132.33FY25 $-11.32FY26 $-2.63

Total Assets

-54.8% YoY

$2.1MFY 2026

FY23 $5.9MFY24 $631.6KFY25 $4.6MFY26 $2.1M

Op. Cash Flow

-22.8% YoY

$-8.1MFY 2026

FY23 $-8.9MFY24 $-8.3MFY25 $-6.6MFY26 $-8.1M

Metric	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Net Income	$-8.8M -94.3%	$-4.5M +54.6%	$-9.9M +33.1%	$-14.9M -20.4%	$-12.4M -145.0%	$-5.0M
Operating Income	$-8.8M -95.0%	$-4.5M +54.7%	$-9.9M +33.2%	$-14.9M -20.7%	$-12.3M -148.8%	$-5.0M
EPS (Diluted)	$-2.63 +76.8%	$-11.32 +91.4%	$-132.33 -478.1%	$-22.89 -16250.0%	$-0.14	—
Total Assets	$2.1M -54.8%	$4.6M +628.8%	$631.6K -89.3%	$5.9M -59.2%	$14.5M +398.4%	$2.9M
Operating Cash Flow	$-8.1M -22.8%	$-6.6M +20.6%	$-8.3M +7.3%	$-8.9M -34.9%	$-6.6M -143.9%	$-2.7M

Get alerted when ALZN's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Alzamend Neuro, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of ALZN

KMT WEALTH MANAGEMENT, LLC
$1.6M1,329,100 sh
Kingsbury Capital Investment Advisors LLC
$1.6M1,329,100 sh
GEODE CAPITAL MANAGEMENT, LLC
$31.6K26,371 sh
VANGUARD FIDUCIARY TRUST CO
$25.2K21,020 sh
VANGUARD CAPITAL MANAGEMENT LLC
$9.1K7,556 sh
Tower Research Capital LLC (TRC)
$4.2K3,517 sh
UBS Group AG
$2.8K2,352 sh
BlackRock, Inc.
$524.00437 sh
SBI Securities Co., Ltd.
$26.0022 sh
IFG Advisory, LLC
$26.0022 sh

Fund	Value	Shares
KMT WEALTH MANAGEMENT, LLC	$1.6M	1,329,100
Kingsbury Capital Investment Advisors LLC	$1.6M	1,329,100
GEODE CAPITAL MANAGEMENT, LLC	$31.6K	26,371
VANGUARD FIDUCIARY TRUST CO	$25.2K	21,020
VANGUARD CAPITAL MANAGEMENT LLC	$9.1K	7,556
Tower Research Capital LLC (TRC)	$4.2K	3,517
UBS Group AG	$2.8K	2,352
BlackRock, Inc.	$524.00	437
SBI Securities Co., Ltd.	$26.00	22
IFG Advisory, LLC	$26.00	22

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put ALZN on your watchlist

Track score changes the day Alzamend Neuro, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is ALZN a good stock to buy?

13F Pro's AI-powered analysis of Alzamend Neuro, Inc. (ALZN) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ALZN are available on the ALZN stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. ALZN is classified as a small company.

Which hedge funds own ALZN?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ALZN. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Alzamend Neuro, Inc.'s investment landscape.